DNAprint Genomics (DNAG)

[mingwan0]

W2P, and as we know PharmEco were one of the investors in the initial funding round.

For those that don't know about the connection:

http://www.contractpharma.com/sep003.htm

Pharm-Eco Laboratories, Inc.
25 Patton Road
Devens, MA 01432
Phone: [phone]
Web site: www.pharmeco.com

Revenues: Approximately $22 million in 1999.

Key Personnel: David Wade, president and chief executive officer; Monica Tamborini, chief financial officer; Richard Gabriel, executive vice president, new ventures; Salah Zahr, Ph.D., executive vice president, scientific affairs; Lee Piver, vice president, marketing and business development; Robert Bondaryk, Ph.D., vice president, corporate development; Dick Einig, Ph.D., director of the quality unit; Tom Saulnier, senior director of engineering; Emile Bellott, Ph.D., director of medi-cinal chemistry; Adel Moussa, Ph.D., assistant director of medi-cinal chemistry; Yesh Sachdeva, Ph.D., director of government contracts and new products; Emile Al-Farhan, Ph.D., senior director of chemical development; Heather Taft, Ph.D., director of chemical development, laboratory operations

Capabilities/Capacities: PharmaSuite is Pharm-Eco’s suite of capabilities, expertise, services, technologies, scientists and chemists and customer-focused alliances. PharmaSuite provides outsourcing for discovery, process R&D and related support services. The company offers a wide array of value-added pharmaceutical services, including API Development, cGMP-compliant manufacturing, analytical services, discovery/medicinal/ combinatorial chemistry services, stability management under ICH guidelines and regulatory services.

Comments: Pharm-Eco re-cently moved into a new 20-acre world-class campus. The new location provides 160,000+ square feet, with capacity for 450+ professionals in three buildings. Pharm-Eco will expand from its 22 state-of-the-art, cGMP-compliant laboratories for API synthesis, re-search and development, to more than 50 labs during the next year. In the long-term, Pharm-Eco plans to expand the Devens campus to 60 acres during the next five years to provide one-stop shopping for API and drug product development and manufacturing. The company also plans to build eight reactor suites within a new cGMP-compliant Pilot Plant, housing up to 500 gallon glass-lined reactors.

In August, 1998, Pharm-Eco formed Universal Pharma Technologies (UPT), a joint venture with UOP. UPT offers a technology portfolio centered on its Simulated Moving Bed (SMB) technology, which provides pharma clients with an advanced tool for accelerating drug development with synthesis/separation process solutions.